What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Formulation: Enteric-coated oral tablet (100 mg base) Dose: Body-surface-area-adjusted; starting dose = 300 mg PO BID; may escalate per 3 + 3 design Administration: By mouth on an empty stomach (AM and PM doses)”In the company’s words, NCT07287917 on ClinicalTrials.gov
- Tested for
- Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
- Main trialPhase 1/2
- “This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: * Cohort 1: Patients with ER+ / HER2- breast cancer receiving fulvestrant and capivasertib * Cohort 2: Patients with unresectable or metastatic cutaneous melanoma receiving pembrolizumab The Phase 1b portion will find the recommended Phase 2 dose (RP2D). The Phase 2 portion will further evaluate clinical activity at the RP2D using response criteria for solid tumors (RECIST 1.1). The study will…”In the company’s words, NCT07287917 on ClinicalTrials.gov
Other drugs for Melanoma (Skin Cancer)
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- ISCIB1+Scancell Ltd · Phase 3
Coming up1
- 28 Feb 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 28 Feb 2028 | Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | |
| Phase 1/2Terminated | 12 Dec 2024 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | |
| Phase 1Completed | 30 Dec 2022 | Oral AMXT 1501 Dicaprate in Combination With DFMO |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026